← Back to patent-cliff list
CX13-608
Tier C — Watch / tradeCX13-608
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Proteasome
Indications (approved)：Multiple myeloma
Regional status
US
-
EU
-
China
Phase II
2020-11-16
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of CX13-608?
Approved indications include: Multiple myeloma.
When does the CX13-608 patent expire?
No public expiry year is available for CX13-608 yet; this page updates once verified.
How do I get a quote for CX13-608 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06